Business
biOasis Announces Formation of Scientific Advisory Board to Advance the Science for the Company’s Blood-Brain Barrier Drug Delivery Platform
biOasis Announces Formation of Scientific Advisory Board to Advance the Science for the Company’s Blood-Brain Barrier Drug Delivery Platform.
About this update from Bioasis Technologies Inc.
[{"type":"text","content":"\n \n BIOASIS \n TECHNOLOGIES INC. (OTCQB:BIOAF;TSX.V:BTI), a \n biopharmaceutical company focused on overcoming the limitations of \n therapeutic drug delivery across the blood-brain barrier (BBB) and into \n the central nervous system for the treatment of neurological diseases \n and disorders, today announced the appointments of Prof. John H. \n Krystal, M.D., Jeffrey L. Cummings, M.D. and John P. Wikswo, Jr., Ph.D. \n to its newly established Scientific Advisory Board (SAB). These \n independent experts will serve as a strategic resource to biOasis as it \n continues to advance the company’s proprietary drug delivery platform. \n Dr. Krystal will serve as chairman of the SAB.\n \n\nThis Smart News Release features multimedia. View the full release here: \nhttp://www.businesswire.com/news/home/20170907006012/en/\n\n \n \n John P. Wikswo, Jr., Ph.D., Gordon A. Cain University Professor at Vanderbilt University, Founding Director of the Vanderbilt Institute for Integrative Biosystems Research and Education (Photo: Business Wire) \n\n\n \n “I’m excited to serve as chair of the biOasis SAB and to work with Mark \n again,” said Dr. Krystal. “Most drugs created to treat central nervous \n system diseases and disorders fail because they aren't optimally \n designed to be delivered in sufficient quantities to the brain. I look \n forward to working with Mark and his team to untap the potential of the \n biOasis platform in the development of differentiated treatments for \n previously untreatable neurological diseases and disorders.”\n \n \n Additional members will be added once their institutions approve their \n membership to the biOasis SAB. The SAB will be comprised of leaders from \n the academic, pharmaceutical and biotechnology industries from \n discovery, translational medicine and clinical development areas The SAB \n will work closely with the biOasis management team to advance the \n development of the Company’s proprietary BBB drug delivery platform, xB3. \n The role of the SAB is to provide strategic guidance and direction for \n the biOasis in-house development programs as well as strategic research \n alliances. The SAB will also play a role in guiding and prioritizing the \n company’s research investment.\n \n \n “I am intrigued by the proprietary xB3 BBB dru...